EGFr: Being 1st may not matter

Epidermal growth factor receptor antagonists appear poised to be the next class of targeted therapies for cancer, attracting both investor and public visibility for companies nearing the milestone of an NDA filing. But even though there are two clear frontrunners in the race to reach the market first, retaining that advantage could prove to be difficult.

The large number of cancers that may be amenable to treatment with the inhibitors is large enough to provide room for multiple marketed products, and at least six EGFr antagonists are in clinical development...